Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
Hypertension. 2002;40:244-250
Published online before print July 29, 2002, doi: 10.1161/01.HYP.0000029095.23198.AD
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
40/3/244    most recent
01.HYP.0000029095.23198.ADv1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Xu, J.
Right arrow Articles by Yang, X.-P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Xu, J.
Right arrow Articles by Yang, X.-P.
Related Collections
Right arrow ACE/Angiotension receptors
Right arrow Animal models of human disease
Right arrow Genetically altered mice
Right arrow Heart failure - basic studies

(Hypertension. 2002;40:244.)
© 2002 American Heart Association, Inc.


Scientific Contributions

Role of AT2 Receptors in the Cardioprotective Effect of AT1 Antagonists in Mice

Jiang Xu; Oscar A. Carretero; Yun-He Liu; Edward G. Shesely; Fang Yang; Alissa Kapke; Xiao-Ping Yang

From the Hypertension and Vascular Research Division (J.X., O.A.C., Y.-H.L., E.G.S., F.Y., A.K., X.-P.Y), Department of Internal Medicine, and the Division of Biostatistics and Research Epidemiology (A.K.), Henry Ford Hospital, Detroit, Mich; and Wuhan University School of Medicine (J.X.), Wuhan, People’s Republic of China.

Correspondence to Xiao-Ping Yang, MD, Hypertension and Vascular Research Division, Henry Ford Hospital, 2799 West Grand Blvd, Detroit, MI 48202–2689. E-mail xpyang1{at}hfhs.org

Angiotensin II (Ang II) acts mainly on two receptor subtypes: AT1 and AT2. Most of the known biological actions of Ang II are mediated by AT1 receptors; however, the role of AT2 receptors remains unclear. We tested the hypothesis that the cardioprotective effects of AT1 receptor antagonists (AT1-ant) after myocardial infarction (MI) are partially mediated by activation of AT2 receptors; thus in AT2 receptor gene knockout mice (AT2-/Y), the effect of AT1-ant will be diminished or absent. MI was induced by ligating the left anterior descending coronary artery. Four weeks later, AT2-/Y and their wild-type littermates (AT2+/Y) were started on vehicle, AT1-ant (valsartan, 50 mg/kg per day), or ACE inhibitor (enalapril, 20 mg/kg per day) for 20 weeks. Basal blood pressure and cardiac function as well as remodeling after MI did not differ between AT2+/Y and AT2-/Y. AT1-ant increased ejection fraction and cardiac output and decreased left ventricular diastolic dimension, myocyte cross-sectional area, and interstitial collagen deposition in AT2+/Y, and these effects were significantly diminished in AT2-/Y. ACE inhibitors improved cardiac function and remodeling similarly in both strains. We concluded that (1) activation of AT2 during AT1 blockade plays an important role in the therapeutic effect of AT1-ant and (2) the AT2 receptor may not play an important role in regulation of cardiac function, either under basal conditions after MI remodeling or in the therapeutic effect of ACE inhibitors.


Key Words: receptors, angiotensin • angiotensin antagonist • myocardial infarction • heart failure • mice




This article has been cited by other articles:


Home page
Exp PhysiolHome page
J. Xu, O. A. Carretero, E. G. Shesely, N.-E. Rhaleb, J. J. Yang, M. Bader, and X.-P. Yang
The kinin B1 receptor contributes to the cardioprotective effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in mice
Exp Physiol, March 1, 2009; 94(3): 322 - 329.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
E. Kaschina, A. Grzesiak, J. Li, A. Foryst-Ludwig, M. Timm, F. Rompe, M. Sommerfeld, U. R. Kemnitz, C. Curato, P. Namsolleck, et al.
Angiotensin II Type 2 Receptor Stimulation: A Novel Option of Therapeutic Interference With the Renin-Angiotensin System in Myocardial Infarction?
Circulation, December 9, 2008; 118(24): 2523 - 2532.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
X. Yan, A. J. T. Schuldt, R. L. Price, I. Amende, F.-F. Liu, K. Okoshi, K. K. L. Ho, A. J. Pope, T. K. Borg, B. H. Lorell, et al.
Pressure overload-induced hypertrophy in transgenic mice selectively overexpressing AT2 receptors in ventricular myocytes
Am J Physiol Heart Circ Physiol, March 1, 2008; 294(3): H1274 - H1281.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
J. Xu, O. A. Carretero, C.-X. Lin, M. A. Cavasin, E. G. Shesely, J. J. Yang, T. L. Reudelhuber, and X.-P. Yang
Role of cardiac overexpression of ANG II in the regulation of cardiac function and remodeling postmyocardial infarction
Am J Physiol Heart Circ Physiol, September 1, 2007; 293(3): H1900 - H1907.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
B. Molavi, J. Chen, and J. L. Mehta
Cardioprotective effects of rosiglitazone are associated with selective overexpression of type 2 angiotensin receptors and inhibition of p42/44 MAPK
Am J Physiol Heart Circ Physiol, August 1, 2006; 291(2): H687 - H693.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
S. Voros, Z. Yang, C. M. Bove, W. D. Gilson, F. H. Epstein, B. A. French, S. S. Berr, S. P. Bishop, M. R. Conaway, H. Matsubara, et al.
Interaction between AT1 and AT2 receptors during postinfarction left ventricular remodeling
Am J Physiol Heart Circ Physiol, March 1, 2006; 290(3): H1004 - H1010.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
R. M. Carey
Cardiovascular and Renal Regulation by the Angiotensin Type 2 Receptor: The AT2 Receptor Comes of Age
Hypertension, May 1, 2005; 45(5): 840 - 844.
[Full Text] [PDF]


Home page
HypertensionHome page
J. Xu, O. A. Carretero, Y. Sun, E. G. Shesely, N.-E. Rhaleb, Y.-H. Liu, T.-D. Liao, J. J. Yang, M. Bader, and X.-P. Yang
Role of the B1 Kinin Receptor in the Regulation of Cardiac Function and Remodeling After Myocardial Infarction
Hypertension, April 1, 2005; 45(4): 747 - 753.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
G. W. Booz
Putting the Brakes on Cardiac Hypertrophy: Exploiting the NO-cGMP Counter-Regulatory System
Hypertension, March 1, 2005; 45(3): 341 - 346.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
M. Benderdour, G. Charron, B. Comte, R. Ayoub, D. Beaudry, S. Foisy, D. deBlois, and C. Des Rosiers
Decreased cardiac mitochondrial NADP+-isocitrate dehydrogenase activity and expression: a marker of oxidative stress in hypertrophy development
Am J Physiol Heart Circ Physiol, November 1, 2004; 287(5): H2122 - H2131.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
O. Johren, A. Dendorfer, and P. Dominiak
Cardiovascular and renal function of angiotensin II type-2 receptors
Cardiovasc Res, June 1, 2004; 62(3): 460 - 467.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
Y. Ishiyama, P. E. Gallagher, D. B. Averill, E. A. Tallant, K. B. Brosnihan, and C. M. Ferrario
Upregulation of Angiotensin-Converting Enzyme 2 After Myocardial Infarction by Blockade of Angiotensin II Receptors
Hypertension, May 1, 2004; 43(5): 970 - 976.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
Y.-H. Liu, X.-P. Yang, E. G. Shesely, S. S. Sankey, and O. A. Carretero
Role of angiotensin II type 2 receptors and kinins in the cardioprotective effect of angiotensin II type 1 receptor antagonists in rats with heart failure
J. Am. Coll. Cardiol., April 21, 2004; 43(8): 1473 - 1480.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
C. M. Bove, Z. Yang, W. D. Gilson, F. H. Epstein, B. A. French, S. S. Berr, S. P. Bishop, H. Matsubara, R. M. Carey, and C. M. Kramer
Nitric Oxide Mediates Benefits of Angiotensin II Type 2 Receptor Overexpression During Post-Infarct Remodeling
Hypertension, March 1, 2004; 43(3): 680 - 685.
[Abstract] [Full Text] [PDF]


Home page
Journal of Renin-Angiotensin-Aldosterone SystemHome page
P. Trongtorsak, T. O Morgan, and L. M. Delbridge
Combined renin-angiotensin system blockade and dietary sodium restriction impairs cardiomyocyte contractility
Journal of Renin-Angiotensin-Aldosterone System, December 1, 2003; 4(4): 213 - 219.
[Abstract] [PDF]


Home page
HypertensionHome page
M. Brede, W. Roell, O. Ritter, F. Wiesmann, R. Jahns, A. Haase, B. K. Fleischmann, and L. Hein
Cardiac Hypertrophy Is Associated With Decreased eNOS Expression in Angiotensin AT2 Receptor-Deficient Mice
Hypertension, December 1, 2003; 42(6): 1177 - 1182.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
R. Chen, M. Iwai, L. Wu, J. Suzuki, L.-J. Min, T. Shiuchi, T. Sugaya, H.-W. Liu, T.-X. Cui, and M. Horiuchi
Important Role of Nitric Oxide in the Effect of Angiotensin-Converting Enzyme Inhibitor Imidapril on Vascular Injury
Hypertension, October 1, 2003; 42(4): 542 - 547.
[Abstract] [Full Text] [PDF]


Home page
Endocr. Rev.Home page
R. M. Carey and H. M. Siragy
Newly Recognized Components of the Renin-Angiotensin System: Potential Roles in Cardiovascular and Renal Regulation
Endocr. Rev., June 1, 2003; 24(3): 261 - 271.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
Y. Oishi, R. Ozono, Y. Yano, Y. Teranishi, M. Akishita, M. Horiuchi, T. Oshima, and M. Kambe
Cardioprotective Role of AT2 Receptor in Postinfarction Left Ventricular Remodeling
Hypertension, March 1, 2003; 41(3): 814 - 818.
[Abstract] [Full Text] [PDF]